SHIELD THERAPEUTICS PLC — AGM Information 2016

Aug 4, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2719G

Shield Therapeutics PLC

04 August 2016

Shield Therapeutics plc

("Shield" or the "Company")

Result of Annual General Meeting

London, UK, 04 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.

- Ends -

For further information please contact:

Shield Therapeutics plc	+44 (0)191 511 8507
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer
NOMAD Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah	+44 (0)20 3100 2222
Financial PR Advisor Consilium Strategic Communications	+44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has an approved product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGAKQDKKBKDBFK